(Q28192984)

https://api.crossref.org/works/10.1007%2FS00392-005-1309-8

Development of aspirin resistance in persons with previous ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-1309-8

Genetic and environmental contributions to platelet aggregation: the Framingham heart study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-1309-8

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-1309-8

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 January 2018

1 reference

12 December 2020

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial

1 reference

12 December 2020

Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Res

1 reference

12 December 2020

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

1 reference

12 December 2020

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

1 reference

12 December 2020

Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy

1 reference

12 December 2020

Randomised trial of prophylactic daily aspirin in British male doctors

1 reference

12 December 2020

Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs

1 reference

12 December 2020

Common variations in platelet glycoproteins: pharmacogenomic implications

1 reference

12 December 2020

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project

1 reference

12 December 2020

Effect of ibuprofen on cardioprotective effect of aspirin

1 reference

12 December 2020

Prior aspirin use in unstable angina predisposes to higher risk: the aspirin paradox

1 reference

12 December 2020

Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin

1 reference

12 December 2020

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

12 December 2020

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

1 reference

12 December 2020

Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina?

1 reference

12 December 2020

Genetic and acquired determinants of individual variability of response to antiplatelet drugs

1 reference

12 December 2020

Final report on the aspirin component of the ongoing Physicians' Health Study

1 reference

12 December 2020

Clinical practice. Aspirin for primary prevention of coronary events

1 reference

12 December 2020